Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis

Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 15. Juni, Seite 108451
1. Verfasser: Takatani, Ayuko (VerfasserIn)
Weitere Verfasser: Koga, Tomohiro, Fujita, Yuya, Fukui, Shoichi, Endo, Yushiro, Shimizu, Toshimasa, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Letter Research Support, Non-U.S. Gov't Anti-MDA5 antibody Dermatomyositis IL-15 Interstitial lung disease Tofacitinib Autoantibodies Piperidines mehr... Protein Kinase Inhibitors Pyrimidines tofacitinib 87LA6FU830 IFIH1 protein, human EC 3.6.1.- Interferon-Induced Helicase, IFIH1 EC 3.6.4.13
Beschreibung
Beschreibung:Date Completed 29.01.2021
Date Revised 29.01.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2020.108451